Chemoresistance is a major therapeutic problem and the current knowledge on cellular mechanisms involved is incomplete. In the present study, we have investigated the possible involvement of Fas-associated death domain-like interleukin-1b-converting enzyme (FLICE)-like inhibitory protein (FLIP) in ovarian cancer resistance by comparing chemosensitive (OV2008) and chemoresistant (C13*) ovarian cancer cells treated with cisplatin in vitro, and/ or transfected with FLIP sense cDNA or FLIP small interfering RNA (siRNA) and determining FLIP protein content, cleavage of caspase-8 and caspase-3 and apoptosis. Cisplatin significantly decreased FLIP protein level, induced cleavage of caspase-8 and caspase-3 and apoptosis in a concentration-dependent manner in cisplatinsensitive but not -resistant cells. While overexpression of FLIP-attenuated cisplatin-induced cleavage of caspase-8 and caspase-3 and apoptosis in chemosensitive cells, downregulation of FLIP in chemoresistant cells by siRNA increased apoptosis induced by cisplatin. These results suggest that FLIP plays a significant role in the regulation of apoptosis in human ovarian cancer cells and their sensitivity to cisplatin. This cell survival factor may be an important determinant in chemoresistance in ovarian cancer and may serve as a molecular target for the development of novel therapy for chemoresistant ovarian cancer.
Introduction
Human ovarian epithelial cancer originates from a simple epithelium covering the surface of the ovary and accounts for approximately 90% of all human ovarian malignancies. It is the most lethal cause of the gynecological malignancies in the Western world. Although platinum derivatives are the first-line chemotherapeutic agents for the treatment of ovarian cancer, chemoresistance remains a major therapeutic problem and the cellular mechanisms involved are poorly understood. Overcoming drug resistance is a key to successful treatment of ovarian cancer (Cheng et al., 2002) .
Recent studies have demonstrated that chemoresistance results in part from an inability of the cells to undergo apoptosis in response to a therapeutic agent, and suppressed apoptosis by intracellular survival factors is important in the development of chemoresistance (Sasaki et al., 2000; Li et al., 2001; Hu et al., 2002; Yuan et al., 2003) . A defect in the activation of the caspase cascade is an important etiological factor in the resistance of cancer cells to cytotoxic agents (Arts et al., 2000) .
The Fas/Fas ligand (FasL) system has been recognized as an important pathway in drug-induced apoptosis and its deficient activation has been implicated in the development of chemoresistance (Schneiderman et al., 1999) . Fas-associated death domain-like interleukin-1b-converting enzyme (FLICE)-like inhibitory protein (FLIP) is a Fas-associated death domain (FADD)-binding suppressor of apoptosis (Irmler et al., 1997) . It exists in two spliced isoforms, derived from C-FLIP gene. Its long isoform, long isoform of FLICElike inhibitory protein (FLIP L ), is a 55-kDa protein containing two N-terminal death effectors domains (DED) and an inactive C-terminal caspase-like domain, whereas its short isoform (FLIP S ) contains only two DEDs (Irmler et al., 1997) . FLIP is an intracellular survival factor structurally similar to caspase-8, and modulates cell surface receptor-mediated cell death processes by inhibiting the activation of caspase-8 through DED-DED interaction (Kinoshita et al., 2000; Vignati et al., 2002; Kim et al., 2003; Wajant, 2003; Xiao et al., 2003) . It has also been shown that FLIP L is phosphorylated in resistant glioma cells and the phosphorylated FLIP L is recruited to DISC to inhibit TRAIL-induced apoptosis (Yang et al., 2003) . Moreover, cisplatin decreased FLIP S content, inhibited FLIP L phosphorylation and facilitated TRAILmediated cell death in human melanoma cells (Song et al., 2003) . These studies suggest that FLIP may play a role in the regulation of apoptosis in different cell types. Although the function of FLIP has been studied in different systems, its role in the chemoresistance in ovarian cancer remains to be determined.
In the present study, we have used a pair of chemosensitive and chemoresistant ovarian cancer cell lines as an in vitro model to examine the regulation of FLIP in cisplatin-mediated apoptosis and its possible role in cisplatin resistance in human ovarian epithelial cancer.
Results
Cisplatin-induced apoptosis in ovarian cancer cells is associated with decreased FLIP protein content and activation of caspase-8 and caspase-3
To compare the effects of different cisplatin concentration (0, 2.5, 5, and 10 mM) on FLIP content and apoptosis in cisplatin-sensitive and cisplatin-resistant ovarian cancer cells, FLIP L and FLIP S protein content and cell nuclear morphology in OV2008 and C13* cells were assessed following cisplatin treatment by Western analysis and Hoechst nuclear staining, respectively. Ovarian cancer cells express both long (FLIP L ) and short (FLIP S ) isoforms of FLIP, that migrate as a 55 and 28 kDa immunoreactive protein, respectively ( Figure 1a ). Cisplatin treatment also resulted in a concentration-dependent decrease in the protein content of both isoforms in cisplatin-sensitive but not -resistant cells (Po0.001; Figure 1a and b). In addition, the presence of cisplatin induced morphological features of apoptosis including decreased cell volume, chromatin condensation, and nuclear fragmentation in chemosensitive cells (OV2008). The increase in apoptotic cell number in response to cisplatin was concentration dependent and significant at 2.5 mM (15 vs 4%; Po0.001; Figure 1c ). In contrast, its resistant variant, C13*, did not undergo cellular or nuclear morphological changes indicative of apoptosis in response to cisplatin (P40.05; Figure 1c ). To determine if the observed downregulation of FLIP content by cisplatin was associated with the activation of caspase-8 and caspase-3, extracts of the ovarian cancer cells (OV2008, C13*) cultured in the absence and presence of cisplatin were assessed for caspase cleavage by Western blotting (Figure 1d ). Cisplatin treatment decreased the intact caspase-8 and caspase-3 contents and increased their respective cleavage fragments in sensitive (OV2008) but not resistant (C13*) cells. Twoway ANOVA on the changes in the cleavage index of caspase-8 (ratio of intensity of cleavage fragments to that of the intact enzyme) indicates a significant cell effect (Po0.001), concentration effect (Po0.001), as well as an interaction between these two factors Intensity of both intact and cleavage fragment of caspase-8 and caspase-3 were quantified and the differences in the extent of cleavage in each experimental group was evaluated by comparing the cleavage index of each group (defined as ratio of the level of cleavage fragments to that of the intact enzyme). **Po0.01, ***Po0.001 (relative to C13* at respective cisplatin concentration; three replicate experiments) (Po0.001) brought about by a marked decrease in the intact enzyme and increase in the cleavage fragments in a concentration-dependent manner in the sensitive but not resistant cells (Figure 1d) . Similarly, ANOVA of the cleavage indices for caspase-3 (Figure 1d ) also showed a significant cell effect (Po0.001), concentration effect (Po0.001) and interaction between cell and concentration (Po0.001). Taken together, these results are consistent with the hypothesis that cisplatin induces apoptosis in sensitive ovarian cancer cells by decreasing FLIP content and that FLIP may play an important role in regulating cisplatin sensitivity in ovarian cancer cells. Figure 2a ). Likewise, addition of cisplatin to OV2008 activated both caspase-8 and caspase-3, as evident by a concentrationdependent increase in the cellular content of their respective cleaved fragments (i.e. 43, 41, 18, and 17 kDa, respectively), and FLIP L overexpression markedly attenuated these responses compared to LacZ control. Two-way ANOVA of the cleavage indices for both caspase-8 and caspase-3 ( Figure 2b ) shows significant effects of FLIP L sense cDNA (Po0.001), cisplatin concentration (Po0.001), and interactions between the two factors (Po0.001). Since cisplatin significantly decreased FLIP S protein level in chemosensitive cells (OV2008) but not in its resistant counterpart (C13*), we have further investigated the role of FLIP S in ovarian cancer chemoresistance by assessing the influence of cisplatin on apoptosis in OV2008 human ovarian cancer cells after FLIP S transfection. Like FLIP L , transient transfection of OV2008 with FLIP S cDNA increased its protein content relative to the vector expressing GFP (control; Po0.001) and attenuated cisplatin-induced apoptosis (Po0.001; Figure 2c ). Compared to GFP control, FLIP S overexpression was accompanied by a marked decrease in cisplatin-induced activation of caspase-8 and caspase-3, with significant changes in cleavage indices (Po0.001; Figure 2d ) for both caspases (effects of FLIP S sense cDNA and cisplatin concentration, and interactions between the two factors). Taken together, these findings suggest that FLIP may play an important role in regulating the sensitivity of ovarian cancer cells to cisplatin treatment.
Downregulation of FLIP sensitizes chemoresistant ovarian cancer cells to cisplatin
If FLIP is indeed a determinant of cisplatin resistance in ovarian cancer cells, it is expected that FLIP downregulation should sensitize the cisplatin-resistant ovarian cells C13* to the cytotoxic action of the chemotherapeutic agent. Cisplatin-resistant ovarian cancer cells (C13*) were transfected with either FLIP L small interfering RNA (siRNA) (0, 12.5, 25, 50, and 100 nM) or its scrambled sequence (control) and treated 24 h thereafter with cisplatin (10 mM) or DMSO (vehicle). ANOVA indicates a significant effect of siRNA (Po0.001) and concentration (Po0.001) as well as a significant interaction between the two factors (Po0.001; Figure 3a ). Transfection of FLIP L siRNA significantly decreased FLIP L content (Po0.001; 50 and 100 nM) but had no effect on FLIP S levels (P40.05). Expression of the scrambled sequence also failed to influence the protein content of both the long and short forms of FLIP. As observed in its effect on FLIP L content, FLIP L siRNA significantly increased apoptotic cell death in a concentration-dependent manner (Po0.001; Figure 3b ). While a significant increase in apoptosis was noted at 12.5 nM of the siRNA (Po0.001), only 10% of the total cells had undergone apoptosis at the highest concentration tested (100 nM). To further examine the involvement of FLIP S in the regulation of apoptosis in ovarian cancer cells, we extended our investigation to assess the effect of cisplatin on apoptosis in cisplatin-resistant human ovarian cancer cells following FLIP S downregulation. Since cDNA for FLIP S share considerable homology (B75%) with FLIP L cDNA, it was technically difficult to design an siRNA for FLIP S that does not interfere with the expression of the long isoform. Thus, in the present study, cisplatin-resistant ovarian cancer cells (C13*) were transfected with FLIP L siRNA, FLIP L þ S siRNA, or scrambled sequence as control (100 nM) and treated 48 h thereafter with cisplatin (0, 10, and 40 mM; 24 h; Figure 3c and d). Relative to the scrambled sequence, FLIP L siRNA decreased protein content of FLIP L (Po0.001 (vs basal and cisplatin at 10 and 40 mM); Figure 3c ) but not of FLIP S (P40.05; Figure 3c ) and significantly increased cisplatin-induced apoptosis (Po0.001; Figure 3d ). FLIP L þ S siRNA decreased protein content of FLIP L (Po0.001) and FLIP S (Po0.001) and induced apoptosis to a significantly but only slightly greater extent than FLIP L siRNA at 40 mM cisplatin (12% vs. 9%; Figure 3d ; Po0.01). Taken together, these findings suggest that FLIP is an important factor in cisplatin chemoresistance, although the long isoform may have a relatively more prominent role.
Discussion
In the present study, we have shown that FLIP L and FLIP S are expressed in human ovarian epithelial cancer cell lines and that cisplatin decreases FLIP L and FLIP S protein content, activates caspase-8 and caspase-3, and induces apoptosis in chemosensitive ovarian cancer cells (OV2008) but not in its resistant variant (C13*). We have also demonstrated that overexpression of FLIP L or FLIP S effectively attenuates cisplatin-induced apoptosis in the sensitive cells, and that downregulation of FLIP in the chemoresistant cells by siRNA sensitizes the cells to cisplatin-induced apoptosis. These findings demonstrate a key regulatory role of FLIP on cisplatin-induced apoptosis in ovarian cancer cells and suggest that FLIP may be an important determinant in cisplatin resistance.
FLIP is an intracellular apoptosis suppressor protein. Although the inhibitory effects of FLIP on apoptosis induced by a variety of stimuli have been demonstrated (Kinoshita et al., 2000; Wang et al., 2000; Xiao et al., 2003) , its role in the regulation of cisplatin sensitivity in ovarian cancer is unknown. Previous studies have shown that FLIP interrupts apoptotic signalling by interaction with FADD and caspase-8, thus blocking the activity of caspase-8 (Irmler et al., 1997; Kinoshita et al., 2000; Vignati et al., 2002; Wajant, 2003; Xiao et al., 2003) , suggesting that the intracellular level of FLIP may determine the sensitivity of tumor cells to a variety of proapoptotic stimuli such as TNFa, FasL, and TRAIL. Our present studies have shown that cisplatin decreases FLIP L and FLIP S contents and induces cell death in overexpression in B-cell lines (A20) has been shown to confer resistance to FasL-mediated cell kills (Wang et al., 2000) . Moreover, FLIP L is constitutively and more intensely expressed in colon cancer than in normal colon tissues, possibly providing a mechanism by which tumor cells escape apoptotic cell death during chemotherapy (Ryu et al., 2001) . However, unlike the present studies that examine both FLIP L and FLIP S , these studies have only studied the role and regulation of the long isoform as the antiapoptotic protein and the significance of FLIP S remains to be determined. Chemoresistance observed in C13* cells seems to be FLIP dependent. The failure of cisplatin to downregulate FLIP and induce apoptosis in the cisplatinresistant cells suggests that this survival factor may be etiologically relevant to chemoresistance; however, how FLIP is involved in the phenomenon is not clear. Recent studies have shown that phenoxodiol-induced apoptosis in ovarian cancer cells is associated with caspase-8 activation and a reduction in FLIP protein content, suggesting that phenoxodiol enhances the sensitivity of ovarian cancer cells to Fas-induced apoptosis in part by removal of FLIP action and activation of caspase-8 (Kamsteeg et al., 2003) . However, while these findings provided interesting correlation between the downregulation of FLIP and the induction of apoptosis, no direct evidence on the possible involvement of FLIP in chemoresistance in ovarian cancer was presented. The present studies provide the first evidence for a role of FLIP in the regulation of chemosensitivity in ovarian cancer. We have shown that FLIP downregulation in the resistant ovarian cancer cells by FLIP L and FLIP L þ S siRNA expression sensitizes the cells to the cytotoxic action of cisplatin in a concentration-dependent manner. In addition, we have also observed that overexpression of FLIP L or FLIP S in chemosensitive cells by sense cDNA rendered them resistant to cisplatin-induced apoptosis. Our findings are supported by the observations that downregulation of FLIP by antisense oligonucleotides or siRNA sensitizes activated mast cells (15), cisplatinresistant HeLa cells (Kamarajan et al., 2003) , and osteosarcoma cells (MG-63) (Kinoshita et al., 2000) to cisplatin-or Fas-mediated apoptosis, although the relative importance of the two FLIP isoforms were not examined in these reports. Taken together, these findings suggest that FLIP is an important determinant in cisplatin resistance.
While some studies indicated that FLIP S is a more potent inhibitor of apoptosis than FLIP L in various systems (Kirchhoff et al., 2000; Krueger et al., 2001; Bin et al., 2002) , others reported that FLIP L plays a more important role in the regulation of apoptosis in other cells by different stimuli, including B-cell line and colon cancer cells (Wang et al., 2000; Ryu et al., 2001) . In the present study, since cisplatin decreased both FLIP L and FLIP S content and their overexpression markedly attenuated cisplatin-induced apoptosis and caspase activation, it is difficult to determine which FLIP isoform plays a more important role in regulating cisplatin sensitivity in ovarian cancer cells. As FLIP L þ S siRNA induced apoptosis to a significantly but only slightly greater extent than FLIP L siRNA at 40 mM cisplatin (12 vs 9%; Figure 3d ; Po0.01), it is possible that the relatively lower incidence of apoptosis could be due to the relatively less effective FLIP S downregulation (50-60% (FLIP S ) vs B75% (FLIP L )), and that a minimum threshold (B75% decrease) must be reached in order to detect additional apoptotic response. Alternatively, cisplatin has multiple effects in the induction of cell death, and FLIP may account for only one component of the intracellular mechanisms leading to cisplatin resistance in ovarian cancer cells. For example, in addition to suppressing FLIP L and FLIP S expression, cisplatin has been shown to upregulate the expression of a number of apoptosis inducers including p53 (Fraser et al., 2003) , Fas and FasL (Schneiderman et al., 1999) , and to downregulate antiapoptotic proteins such as X-linked inhibitor of apoptosis protein (XIAP) (Li et al., 2001 ) and protein kinase B/Akt (Asselin et al., 2001) . Indeed, whereas overexpression of XIAP or Akt rendered chemosensitive ovarian cancer cells resistant to cisplatin, downregulation of these proteins in chemoresistant counterparts by antisense or dominant-negative expression facilitated cisplatin-induced apoptosis (Asselin et al., 2001; Li et al., 2001; Fraser et al., 2003) , suggesting that these cell survival factors may also be involved in the regulation of cisplatin sensitivity. Since XIAP is acting downstream of FLIP on the caspasemediated death pathway, the possibility exists that XIAP and Akt are key determinants of cisplatin resistance, and that FLIP-mediated resistance may represent a minor component and is independent of XIAP and Akt. Alternately, the relatively low incidence of apoptosis could be due to insufficient FLIP downregulation, as the siRNA was only able to suppress FLIP content by about 60% as compared to B90% by cisplatin.
In the present study, we have demonstrated that cisplatin decreases FLIP protein content in human ovarian cancer cells, although precisely how cisplatin elicits this response is not known. The decrease in FLIP L and FLIP S levels did not appear to be due to a general cytotoxic effect of the anticancer agent, since earlier studies under identical experimental conditions indicate that cisplatin treatment increases Fas and FasL expression (Schneiderman et al., 1999) and activates downstream caspases (Asselin et al., 2001) . Moreover, DNA damage-inducible genes, such as gadd153, gadd45, p21, and c-jun, have also been shown to be upregulated by cisplatin in this cell system (Delmastro et al., 1997) . The action of cisplatin is associated with the formation of DNA adducts (Fichtinger-Schepman et al., 1985; Eastman, 1986 ) and its ability to trigger apoptosis. Apoptosis induced by cisplatin can be inhibited by cycloheximide, suggesting that synthesis of new proteins may be required (Barry et al., 1990) . FLIP, with a consensus sequence of a caspase-3-mediated cleavage site (DXXD), is a substrate of caspase-3 and cotreatment of cisplatin and TRAIL in head and neck squamous cell carcinoma decreased FLIP S content through caspase-3-mediated cleavage and -induced apoptosis (Kim et al., 2003) . The latter response was inhibited by FLIP S overexpression. Fas-mediated FLIP L cleavage has also been demonstrated in B cells (Hennino et al., 2000) . Alternatively, it is possible that the decrease in FLIP content subsequent to cisplatin challenge may be a consequence of proteasome-mediated processing, initially involving ubiquitination and subsequently degradation of the FLIP molecule (Fukazawa et al., 2001) . The regulation of FLIP in human ovarian cancer cells remains to be investigated. Moreover, previous studies have demonstrated that cisplatin decreased FLIP S expression in melanoma cells (Song et al., 2003) . Whether the downregulation of FLIP content in ovarian cancer cells by cisplatin involves suppressed gene transcription and/or post-translational processing via caspase cleavage or proteasome degradation, remains to be determined.
In summary, we have tested the hypothesis that the inability of cisplatin to downregulate FLIP may in part be a contributing factor for chemoresistance in human ovarian cancer. We hereby report that: (1) cisplatin decreases FLIP content and induces apoptosis in the cisplatin-sensitive cells but not in the -resistant counterpart, (2) overexpression of FLIP by cDNA transfection is effective in attenuating cisplatin-induced apoptosis in chemosensitive cells, and (3) FLIP siRNA expression facilitates apoptotic cell death in chemoresistant counterpart induced by cisplatin. These findings suggest that downregulation of FLIP may increase the sensitivity of chemoresistant cells to cisplatin and may be a potential therapeutic strategy for cisplatin-resistant ovarian cancer associated with FLIP overexpression.
Materials and methods

Reagents
Roswell Park Memorial Institute 1640 (RPMI 1640) supplemented with 10% (vol/vol) fetal bovine serum (FBS), streptomycin (100 mg/ml), penicillin (100 units/ml), and fungizone (0.625 mg/ml) were used for cell cultures (all from Life Technologies Inc., Burlinton, Ontario, Canada). Cisplatin and DMSO were from Sigma. pcDNA3.1/containing GFP expression vector and pEF6/V5-His containing LacZ were from Invitrogen Corporation (Carlsbad, CA, USA). siRNA for FLIP L and FLIP L þ S were supplied by Dharmacon (Dallas, TX, USA). Primary antibodies used were anti-FLIP mouse monoclonal IgG (ALX-804-428, Clone NF6; Alexis Biochemicals, San Diego, CA, USA), anti-caspase-8 mouse monoclonal IgG (9746, Clone 1C12; Cell signaling, Beverly, MA, USA), anti-caspase-3 rabbit polyclonal IgG (556425; BD Pharmingen, San Diego, CA, USA), and anti-GAPDH mouse monoclonal IgG (ab8245, Clone 6C5; Abcam, Cambridge, MA, USA).
Cell culture
Cisplatin-sensitive (OV2008) and its -resistant variant (C13*) cell lines (4.8 Â 10 5 cells/well) were plated on six-well plates for 20 h in RPMI 1640 with 10% FBS (Asselin et al., 2001) .
Preparing of plasmid cDNA
The cDNA fragment ending the open-reading frame of human FLIP L was amplified by PCR reaction using a set of primers: 5 0 -TGTGTAGGAGAGGATAAGTTTC-3 0 (forward) and 5 0 -GAGTAGGATGGCTGCTGAAG-3 0 (reverse) and the MGC: 2044 clone containing the full length of FLIP L cDNA as a template. The primers were designed based on the human FLIP L sequences (GeneBank Accession no. U97074) and the PCR product was subcloned into pEF6/V5-His-TOPO expression vector using pEF6/V5-His-TOPO s TA cloning kit according to the manufacturer's instruction (Invitrogen, Carlsbad, CA, USA). The sense hFLIP LpEF6/V5-His constructs were verified by automated sequence analysis. The cDNA fragment ending the open-reading frame of human FLIPs was prepared previously . 
Determination of apoptosis
At the end of the culture period, cells attached to the growth surface were removed by trypsin treatment (trypsin (0.05%), EDTA (0.53 mM); 371C, 1 min). Attached and detached cells were pooled, pelleted, and resuspended in neutral-buffered formalin (10%) containing Hoechst 33258 dye (6.25 ng/ml). At 24 h thereafter, cells were spotted onto slides and assessed for typical apoptotic nuclear morphology (nuclear shrinkage, condensation, and fragmentation) under a fluorescence microscope with appropriate filter combination (DAPI filter). At least 200 cells/treatment groups were counted and selected fields and blinded slides assessed randomly to avoid experimental bias (Sasaki et al., 2000) .
Protein extraction and Western blotting
Cells were sonicated in lysis buffer containing 150 mM NaCl, 0.1% SDS, 0.5% sodium deoxycholate, 0.1% NP-40, PBS, 1 mM phenylmethylsulfonyl fluoride, 10 mg/ml aprotinin, and 1 mM Na 3 (VO 4 ). Equivalent amounts of total protein (50-80 mg) were loaded onto 12% acrylamide gels, separated by electrophoresis and electrotransferred onto nitrocellulose membranes . Loading between lanes was assessed by Ponca-S staining. Membranes were blocked in Blotto (5% skim milk in Tris-buffered saline-Tween; 1 h) and subsequently incubated with primary antibodies (anti-FLIP, 1 : 500; anti-caspase-8, 1 : 1000; anti-caspase-3 1 : 2000, or 0.5 h at room temperature with anti-GAPDH, 1 : 20 000) in Blotto for 16-20 h at 41C. Primary antibodies were detected with horseradish peroxidase-conjugated goat IgG raised against the corresponding species (goat anti-rabbit for anti-caspase-3 (1 : 4000) and goat anti-mouse for anti-FLIP (1 : 1000), anticaspase-8 (1 : 2000), and anti-GAPDH (1 : 20 000)) in Blotto (1 h, RT; Schneiderman et al., 1999) . Peroxidase activity was detected by the Enhanced Chemiluminescence Detection Kit, recorded on HyperFilm MP (both from Amersham Pharmacia Biotech Arlington, IL, USA) and analysed (Scion Image software, Scion Inc). To quantify changes in FLIP protein content due to treatment, the ratio of the signal of FLIP and that of GAPDH of the corresponding lane was calculated and expressed as fold of the value determined from an internal standard (interassay pool) to correct for loading differences between lanes and variability between replicate experiments, respectively.
Statistical analysis
Results are expressed as the mean7s.e.m. of at least three independent experiments. Data were analysed using one-or two-way ANOVA and with Bonferoni post-test to assess differences between experimental groups (PRISM 4.0; GraphPad Software Inc.). Statistical significance was inferred at (Po0.05). 
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